RELAPSED/REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED/REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New cell therapy IMV102 targets Hard-to-Treat multiple myeloma in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called IMV102 in 30 people with multiple myeloma that has returned or not responded to at least three prior therapies. Participants receive a single infusion of IMV102, and researchers will monitor safety and how well it controls the c…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: EARLY_PHASE1 • Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd • Aim: Disease control
Last updated May 26, 2026 10:32 UTC
-
New hope for Tough-to-Treat myeloma: experimental drug LBL-034 enters human trials
Disease control Recruiting nowThis study is testing an experimental drug called LBL-034 in people whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to find the safest dose and to see if the drug can shrink tumors. About 342 adults will take part in this early…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated May 26, 2026 10:32 UTC
-
Supercharged immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy, boosted with a protein called IL-15, in people with multiple myeloma or plasma cell leukemia that has come back or not responded to treatment. The goal is to see if these enhanced immune cells can shrink or eliminate the cancer. …
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated May 26, 2026 10:30 UTC
-
New Dual-Targeting CAR t therapy takes on Tough-to-Treat myeloma
Disease control Recruiting nowThis study tests a new treatment called AZD0120 for people with multiple myeloma that has returned or stopped responding to at least three prior therapies. AZD0120 is a personalized cell therapy that uses a patient's own immune cells, modified to target two proteins (CD19 and BCM…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 26, 2026 10:29 UTC
-
New CAR-T therapy targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called CT0596 CAR-T cells for people with multiple myeloma or plasma cell leukemia that has come back or not responded to standard therapies. About 24 adults will receive the therapy to see if it is safe and how well it works. The goal…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: EARLY_PHASE1 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 26, 2026 10:24 UTC
-
New hope for Hard-to-Treat multiple myeloma: first human trial begins
Disease control Recruiting nowThis early-stage study tests a new drug called ISB 2001 in people with multiple myeloma that has returned or stopped responding to standard treatments. The main goals are to check the drug's safety and see if it can fight the cancer. About 200 participants will receive the drug i…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Ichnos Sciences SA • Aim: Disease control
Last updated May 26, 2026 08:20 UTC
-
New hope for multiple myeloma patients with a specific genetic change
Disease control Recruiting nowThis study tests a new drug called sonrotoclax, alone or with other medicines, in people with a type of blood cancer (multiple myeloma) that has come back or not responded to treatment. The cancer must have a specific genetic change called t(11;14). The goal is to see if the drug…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New shot combo aims to control hard-to-treat myeloma
Disease control Recruiting nowThis study tests a new combination of two drugs (elranatamab and isatuximab) given as shots under the skin for people with multiple myeloma that has come back or not responded to at least two prior treatments. The goal is to see if the combination can shrink or control the cancer…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Gene-Edited immune cells take on Hard-to-Treat blood cancer
Disease control Recruiting nowThis early-phase study tests CB-011, a CRISPR-edited immune cell therapy, in 50 adults with multiple myeloma that has returned or stopped responding to at least three prior treatments. The therapy uses donor cells engineered to target and destroy cancer cells. The main goals are …
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Caribou Biosciences, Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New drug duo takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests a new experimental drug, REGN7945, combined with another experimental drug, linvoseltamab, in people whose multiple myeloma has returned or not responded to at least three prior treatments. The goal is to see if the combination is safe and works better than linvo…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
New CAR-T therapy aims to outperform standard drugs in Tough-to-Treat myeloma
Disease control Recruiting nowThis study tests a new treatment called AZD0120, which uses a patient's own immune cells engineered to attack myeloma cells. It is for people with relapsed refractory multiple myeloma, meaning their cancer has returned or not responded to prior treatments. About 508 participants …
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 19, 2026 11:59 UTC
-
New hope for Tough-to-Treat multiple myeloma: experimental combo enters phase 2
Disease control Recruiting nowThis study tests a new drug called cemsidomide combined with dexamethasone in about 100 adults whose multiple myeloma has returned or stopped responding after at least three prior treatments. The goal is to see how well the combination shrinks tumors and how safe it is. Participa…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: C4 Therapeutics, Inc. • Aim: Disease control
Last updated May 19, 2026 11:49 UTC
-
Researchers track Real-World myeloma care to improve future treatments
Knowledge-focused Recruiting nowThis study follows about 300 people whose multiple myeloma has come back or stopped responding to treatment. Over 24 months, researchers will observe the standard treatments patients receive in real clinics, not in a controlled lab. The goal is to see how well these treatments wo…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA
Sponsor: Janssen Pharmaceutica N.V., Belgium • Aim: Knowledge-focused
Last updated May 22, 2026 14:05 UTC